NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 982 DKK | -0.65% |
|
+4.89% | +40.67% |
| 09:10pm | Novo Nordisk to Face Senate Panel Subpoena Vote Over Ozempic, Wegovy Prices | MT |
| 08:09pm | Sector Update: Health Care Stocks Decline Tuesday Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
2024-08-07
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
988.4
DKK
Average target price
929.5
DKK
Spread / Average Target
-5.96%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.67% | 631B | |
| +49.39% | 779B | |
| -6.14% | 354B | |
| +20.97% | 333B | |
| +8.71% | 301B | |
| +16.75% | 249B | |
| -1.19% | 216B | |
| +10.85% | 214B | |
| +4.73% | 163B | |
| -2.36% | 159B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- US Senate Committee Warns of Potential Healthcare Bankruptcy Due to Novo Nordisk's Wegovy
